MICHAEL GONZALEZ: Open Payments
NPI 1942536313 · ELSA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$902 in 45 payments from 10 companies in 2025. Trend: 2023 $402 · 2024 $535 · 2025 $902
Food & beverage: $902
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $181 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $167 |
| Lilly USA, LLC | 6 | $119 |
| Zimmer Biomet Holdings, Inc. | 1 | $103 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $101 |
| AstraZeneca Pharmaceuticals LP | 5 | $97 |
| Abbott Laboratories | 3 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Novo Nordisk Inc | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
Products named: OTEZLA, Kerendia, MOUNJARO, Gel-One Cross-linked Hyaluronate, JARDIANCE, FARXIGA, FREESTYLE LIBRE 3, XIFAXAN.
Industry payments across TX — which companies pay providers there.
